Stifel Nicolaus analyst James Condulis maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $80.00.
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback